Category: 871022-62-7

A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, Computed Properties of C11H21FN2O2, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 871022-62-7, Name is tert-Butyl ((4-fluoropiperidin-4-yl)methyl)carbamate, molecular formula is C11H21FN2O2. In a Patent, authors is ，once mentioned of 871022-62-7

The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

I hope this article can help some friends in scientific research. I am very proud of our efforts over the past few months and hope to 871022-62-7, help many people in the next few years.Computed Properties of C11H21FN2O2

Reference：
Piperidine – Wikipedia,
Piperidine | C5H18780N – PubChem

 

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 871022-62-7, name is tert-Butyl ((4-fluoropiperidin-4-yl)methyl)carbamate, introducing its new discovery. Formula: C11H21FN2O2

Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1

Inhibition of lysine specific demethylase 1 (LSD1) has been shown to induce the differentiation of leukemia stem cells in acute myeloid leukemia (AML). Irreversible inhibitors developed from the nonspecific inhibitor tranylcypromine have entered clinical trials; however, the development of effective reversible inhibitors has proved more challenging. Herein, we describe our efforts to identify reversible inhibitors of LSD1 from a high throughput screen and subsequent in silico modeling approaches. From a single hit (12) validated by biochemical and biophysical assays, we describe our efforts to develop acyclic scaffold-hops from GSK-690 (1). A further scaffold modification to a (4-cyanophenyl)glycinamide (e.g., 29a) led to the development of compound 32, with a Kd value of 32 nM and an EC50 value of 0.67 muM in a surrogate cellular biomarker assay. Moreover, this derivative does not display the same level of hERG liability as observed with 1 and represents a promising lead for further development.

The proportionality constant is the rate constant for the particular unimolecular reaction. the reaction rate is directly proportional to the concentration of the reactant. I hope my blog about 871022-62-7 is helpful to your research. Formula: C11H21FN2O2

Reference£º
Piperidine – Wikipedia,
Piperidine | C5H18783N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.871022-62-7,tert-Butyl ((4-fluoropiperidin-4-yl)methyl)carbamate,as a common compound, the synthetic route is as follows.

The mixture of tert-butyl N-[(4-fluoro-4- piperidyl)methyl]carbamate (150.00 mg, 645.74 //mol, 1.00 eq) and 9H-fluoren-9-ylmethyl carbonochloridate (250.58 mg, 968.61 //mol, 1.50 eq) were dissolved in THF (20.00 mP) and H20 (4.00 mP), to which NaHCCp (162.75 mg, 1.94 mmol, 75.35 //F, 3.00 eq) was added in one portion. The resulting mixture was then stirred at 15 C for 14 h. The reacting solution was diluted with water (50 mP) and extracted with EA (50 mP x 3). The combined organic layers were concentrated under reduced pressure. The residue was purified by silica gel chromatography (pure PE to PE:EA = 5:1) to afford 9H-fluoren-9-ylmethyl 4-[(tert- butoxycarbonylamino)methyl]-4-fluoro-piperidine-l -carboxylate (163.00 mg, 358.61 //mol, 55.54% yield) as an off-white solid. The product was confirmed by PC-MS and used directly for the next step without further purification, 871022-62-7

871022-62-7 tert-Butyl ((4-fluoropiperidin-4-yl)methyl)carbamate 53415226, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; NEWAVE PHARMACEUTICAL INC.; CHEN, Yi; (475 pag.)WO2020/41406; (2020); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

 

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.871022-62-7,tert-Butyl ((4-fluoropiperidin-4-yl)methyl)carbamate,as a common compound, the synthetic route is as follows.

[00344] Step a: A mixture of 3-((3-amino-2-chlorophenyl)thio)-6-chloropyrazin-2- amine (200 mg, 0.696 mmol) and tert-butyl ((4-fluoropiperidin-4-yl)methyl)carbamate (243 mg, 1.045 mmol), and DIPEA (0.6 mL, 3.48 mmol) in NMP (2 mL) was stirred for 16 h at 150 C. After cooling to RT, the reaction mixture was poured into a separation funnel containing brine and it was extracted with EtOAc (3 x 5 mL). The combined organic phases were dried over MgS04, filtered and the volatiles were removed under reduced pressure. The resulting residue was purified by silica chromatography (0 to 10% gradient of MeOH DCM) to give tert-butyl ((l-(6-amino-5- ((3-amino-2-chlorophenyl)thio)pyrazin-2-yl)-4-fluoropiperidin-4-yl)methyl)carbamate (285 mg, 0.590 mmol). MS m/z 483.1 (M+H)+.

871022-62-7, As the paragraph descriping shows that 871022-62-7 is playing an increasingly important role.

Reference£º
Patent; NOVARTIS AG; CHEN, Zhuoliang; DORE, Michael; FORTANET, Jorge Garcia; KARKI, Rajesh; KATO, Mitsunori; LAMARCHE, Matthew J.; PEREZ, Lawrence Blas; WILLIAMS, Sarah; SENDZIK, Martin; WO2015/107494; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem